We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
Read MoreHide Full Article
Key Takeaways
{\"0\":\"Zoetis gained CVMP support for Portela, a monoclonal antibody for feline OA pain relief.\",\"1\":\"Portela offers up to 3 months of pain relief with one jab and was well-tolerated in clinical studies.\",\"2\":\"Portela will complement Solensia, giving vets and owners both monthly and quarterly OA pain therapy options.\"}
Zoetis (ZTS - Free Report) announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) has issued a positive opinion for its investigational monoclonal antibody (mAb) therapy, Portela (relfovetmab). The recommendation supports granting marketing authorization for the candidate, which has been developed to help relieve pain associated with osteoarthritis (OA) in cats.
Based on the CVMP’s recommendation, Zoetis expects the European regulatory body to communicate a final decision during the fourth quarter of 2025. Subject to a favorable outcome, the company anticipates making Portela commercially available in the EU in 2026.
What an EU Nod for Portela Will Mean for ZTS?
Zoetis’ Portela could represent a meaningful advance in veterinary medicine if it secures an EU approval, as it would be the first long-acting anti-NGF mAb therapy available for cats. Designed to provide up to three months of OA pain relief with a single injection, the therapy addresses a significant unmet need in feline care, where treatment options for chronic pain are limited. The CVMP’s positive opinion reflects a favorable review of both safety and efficacy data, with studies showing that the candidate was well tolerated, even among cats with early-stage kidney disease.
ZTS shares have lost 9.1% year to date compared with the industry’s 10.9% growth.
Image Source: Zacks Investment Research
For Zoetis, the potential approval of Portela not only reinforces its leadership in the animal health sector but also expands its innovative portfolio in companion animal therapeutics. By offering veterinarians and pet owners a novel, convenient option for managing OA pain, the company stands to strengthen its market presence in the EU and beyond, thereby boosting its revenue stream.
OA is a progressive joint disease that causes pain and mobility issues in cats, with up to 40% showing clinical signs, though only 18% are formally diagnosed. Early identification and treatment are critical, as chronic pain not only limits movement but also affects sleep, cognition and overall quality of life.
ZTS’ Portela Set to Complement Librela for OA Pain in Cats
Zoetis is positioning Portela to extend its OA pain franchise, complementing its established anti-NGF mAb therapy, Solensia (frunevetmab). While Solensia, approved in more than 40 countries, offers monthly pain relief, Portela (if approved) would provide a long-acting alternative with dosing required only once every three months. This dual offering would allow veterinarians and cat owners to choose between monthly and quarterly treatment schedules, broadening Zoetis’ reach in the feline OA market and reinforcing its leadership in veterinary pain management.
Portela highlights Zoetis’ strategy of disruptive innovation aimed at addressing unmet needs in companion animal health. With Solensia already demonstrating clinical and real-world success, the addition of Portela could deepen Zoetis’ penetration into the growing feline OA segment, while also improving treatment adherence due to its less frequent dosing schedule.
In the past 60 days, estimates for CorMedix’s earnings per share have increased from $1.10 to $1.52 for 2025. During the same time, earnings per share estimates for 2026 have increased from $1.46 to $2.12. Year to date, shares of CRMD have surged 59.7%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 34.85%.
In the past 60 days, estimates for Pharming Group’s 2025 loss per share have narrowed from 40 cents to 10 cents. For 2026, PHAR’s earnings per share estimate has improved from 7 cents to 27 cents. PHAR stock has risen 45.8% year to date.
Pharming Group’s earnings beat estimates in two of the trailing four quarters and missed on the remaining two occasions, delivering an average negative surprise of 39.14%.
In the past 60 days, estimates for Kiniksa Pharmaceuticals’ 2025 earnings per share have increased from 74 cents to $1.03. Earnings per share estimate for 2026 has increased from $1.19 to $1.60 during the same period. KNSA stock has surged 87.5% year to date.
Kiniksa Pharmaceuticals’ earnings beat estimates in two of the trailing four quarters and missed on the remaining two occasions, delivering an average negative surprise of 330.56%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
Key Takeaways
Zoetis (ZTS - Free Report) announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) has issued a positive opinion for its investigational monoclonal antibody (mAb) therapy, Portela (relfovetmab). The recommendation supports granting marketing authorization for the candidate, which has been developed to help relieve pain associated with osteoarthritis (OA) in cats.
Based on the CVMP’s recommendation, Zoetis expects the European regulatory body to communicate a final decision during the fourth quarter of 2025. Subject to a favorable outcome, the company anticipates making Portela commercially available in the EU in 2026.
What an EU Nod for Portela Will Mean for ZTS?
Zoetis’ Portela could represent a meaningful advance in veterinary medicine if it secures an EU approval, as it would be the first long-acting anti-NGF mAb therapy available for cats. Designed to provide up to three months of OA pain relief with a single injection, the therapy addresses a significant unmet need in feline care, where treatment options for chronic pain are limited. The CVMP’s positive opinion reflects a favorable review of both safety and efficacy data, with studies showing that the candidate was well tolerated, even among cats with early-stage kidney disease.
ZTS shares have lost 9.1% year to date compared with the industry’s 10.9% growth.
Image Source: Zacks Investment Research
For Zoetis, the potential approval of Portela not only reinforces its leadership in the animal health sector but also expands its innovative portfolio in companion animal therapeutics. By offering veterinarians and pet owners a novel, convenient option for managing OA pain, the company stands to strengthen its market presence in the EU and beyond, thereby boosting its revenue stream.
OA is a progressive joint disease that causes pain and mobility issues in cats, with up to 40% showing clinical signs, though only 18% are formally diagnosed. Early identification and treatment are critical, as chronic pain not only limits movement but also affects sleep, cognition and overall quality of life.
ZTS’ Portela Set to Complement Librela for OA Pain in Cats
Zoetis is positioning Portela to extend its OA pain franchise, complementing its established anti-NGF mAb therapy, Solensia (frunevetmab). While Solensia, approved in more than 40 countries, offers monthly pain relief, Portela (if approved) would provide a long-acting alternative with dosing required only once every three months. This dual offering would allow veterinarians and cat owners to choose between monthly and quarterly treatment schedules, broadening Zoetis’ reach in the feline OA market and reinforcing its leadership in veterinary pain management.
Portela highlights Zoetis’ strategy of disruptive innovation aimed at addressing unmet needs in companion animal health. With Solensia already demonstrating clinical and real-world success, the addition of Portela could deepen Zoetis’ penetration into the growing feline OA segment, while also improving treatment adherence due to its less frequent dosing schedule.
Zoetis Inc. Price and Consensus
Zoetis Inc. price-consensus-chart | Zoetis Inc. Quote
ZTS’ Zacks Rank & Stocks to Consider
Zoetis currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are CorMedix (CRMD - Free Report) , Pharming Group (PHAR - Free Report) and Kiniksa Pharmaceuticals (KNSA - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for CorMedix’s earnings per share have increased from $1.10 to $1.52 for 2025. During the same time, earnings per share estimates for 2026 have increased from $1.46 to $2.12. Year to date, shares of CRMD have surged 59.7%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 34.85%.
In the past 60 days, estimates for Pharming Group’s 2025 loss per share have narrowed from 40 cents to 10 cents. For 2026, PHAR’s earnings per share estimate has improved from 7 cents to 27 cents. PHAR stock has risen 45.8% year to date.
Pharming Group’s earnings beat estimates in two of the trailing four quarters and missed on the remaining two occasions, delivering an average negative surprise of 39.14%.
In the past 60 days, estimates for Kiniksa Pharmaceuticals’ 2025 earnings per share have increased from 74 cents to $1.03. Earnings per share estimate for 2026 has increased from $1.19 to $1.60 during the same period. KNSA stock has surged 87.5% year to date.
Kiniksa Pharmaceuticals’ earnings beat estimates in two of the trailing four quarters and missed on the remaining two occasions, delivering an average negative surprise of 330.56%.